Between July 16 , 2009 , and March 7 , 2011 ( when enrolment was prematurely terminated ) , 284 patients received initial bevacizumab and docetaxel ; 185 ( 65 % ) were randomly assigned ( 91 to bevacizumab and capecitabine versus 94 to bevacizumab only ) .